What Fueled The Previous Growth In The Influenza Treatment Market?
The influenza treatment market has seen considerable growth due to a variety of factors.
• The influenza treatment market has grown steadily in recent years. It will increase from $6.6 billion in 2024 to $6.9 billion in 2025, reflecting a CAGR of 4.5%.
This growth is attributed to the increasing number of annual influenza cases, higher government funding for influenza research, public awareness campaigns promoting vaccination, the establishment of global influenza surveillance systems, and an expansion of healthcare facilities.
What Can Be Expected from the Influenza Treatment Market Size?
The influenza treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The influenza treatment market is forecast to reach $8.16 billion by 2029 at a CAGR of 4.3%.
This growth is driven by new antiviral drugs, expanding vaccination programs, healthcare infrastructure improvements, aging populations, and new treatment developments. Trends include universal vaccine progress, innovations in vaccine delivery, AI and big data integration, personalized medicine, and increased pharma collaborations.
What Are the Critical Driver Fuelling The Influenza Treatment Market's Growth?
The rise in contagious respiratory illnesses is anticipated to drive the growth of the influenza treatment market. Contagious respiratory diseases, such as influenza, measles, and respiratory syncytial virus (RSV) infections, are transmitted through infected individuals, their bodily fluids, or contaminated surfaces. Factors such as dense populations, poor healthcare infrastructure, antibiotic misuse, and increased international travel are contributing to this rise. Influenza treatments include antiviral drugs and vaccines for respiratory illnesses like flu and COVID-19. For example, in September 2023, the CDC reported a surge in RSV-related hospitalizations in the U.S. from 2 to 7 per 100,000 people between August 5-19, 2023. This growing prevalence of contagious respiratory illnesses is driving the market.
How Is The Influenza Treatment Market segmented?
The influenza treatment market covered in this report is segmented –
1) By Product Type: Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Other Products
2) By Route Of Administration: Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels
Subsegments:
1) By Peramivir: Intravenous Peramivir, Peramivir Injection
2) By Zanamivir: Inhaled Zanamivir, Zanamivir Diskhaler
3) By Oseltamivir Phosphate: Oseltamivir Capsules, Oseltamivir Oral Suspension
4) By Baloxavir Marboxil: Baloxavir Tablets, Baloxavir Granules For Oral Suspension
5) Other Products: Rimantadine, Amantadine
Pre-Book The Influenza Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Influenza Treatment Industry?
Prominent businesses in the influenza treatment market are strategizing to broaden their product range by introducing novel solutions like single-dose oral medications for influenza treatment to increase patient adherence, enhance treatment results, and secure a greater market share. A single-dose oral medication is a specifically formulated to cure influenza (flu) with only one dose, making the treatment procedure simpler. For example, in August 2022, Genentech Inc., a biotechnology firm based in the US, reported that the U.S. Food and Drug Administration (FDA) had approved Xofluza (Baloxavir Marboxil). Xofluza represents the first and only single-dose oral medicine that provides a streamlined and effective method for handling acute uncomplicated influenza in children from five (5) to under 12 years of age, who have been symptomatic for less than 48 hours and other respiratory viruses.
Who Are the Key Players In The Influenza Treatment Market?
Major companies operating in the influenza treatment market are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline Plc
• Takeda Pharmaceutical Company
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• Fujifilm Holdings Corporation
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceuticals Inc.
• Regeneron Pharmaceuticals Inc.
• Daiichi Sankyo Company Limited.
• Chugai Pharmaceutical Co. Ltd.
• Sun Pharmaceutical Industries Limited
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Lupin Limited
• NATCO Pharma Limited
• BioCryst Pharmaceuticals Inc.
• NanoViricides Inc.
What Is The Most Dominant Region In The Influenza Treatment Market?
North America was the largest region in the influenza treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
